The Fetal Outcome in a Randomized Double-Blind Controlled Trial of Labetalol versus Placebo in Pregnancy-Induced Hypertension

Pickles, C. J.; Symonds, E. M.; Pipkin, FionaBroughton

doi:10.1097/00132582-198910000-00029

Cited by 12 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported in a random double blind placebo controlled study of mixed parity, with an excess of primigravidae (77 per cent) in the placebo group compared with the labetalol group (66 per cent) (Pickles et al, 1989). There was 14 per cent intra-uterine growth retardation in the labetalol group and 7 per cent in the placebo group.…”

Section: Discussionsupporting

confidence: 84%

“…This is only the second report of a possible effect of maternal labetalol on fetal growth from a random controlled study where the control allows comparison with the natural history of late onset hypertension in pregnancy (Pickles et al, 1989). The birth weight centile distribution for the babies born of multigravid controls fits the normal Abcrdeen population birth weight centile distribution (Thomson et al, 1968).…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Intra-uterine growth retardation and maternal labetatol treatment in a random allocation controlled study

Cruickshank¹,

Campbell²,

Robertson³

et al. 1992

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Intra-uterine growth retardation (IUGR) is the main contributory factor in the increased perinatal morbidity and mortality associated with pregnancy induced hypertension. Seventy-six primigravidae and 38 parous women with non-proteinuric hypertension (diastolic blood pressure > 90 mmHg) and singleton pregnancies were allocated at random to receive either labetalol or no antihypertensive treatment. At recruitment maternal age, blood pressure and gestational age were similar in both treatment and control groups. For primigravidae 16 per cent (7/45) of the controls delivered a baby with weight less than the 10th centile for gestational age compared with 19 per cent (6/31) in the labetalol treated group. A birth weight less than the 10th centile for gestational age occurred in 2 out of 18 multigravid controls and 4 out of 20 of the multigravid labetalol treated group. There were more admissions to the neonatal unit for the babies of kdbetalol treated mothers.A limited meta-analysis of the results combined with those of two other controlled trials suggests that the drug contributes to intra-uterine growth retardation ( P < 0.05).The possibility of labetalol having a direct adverse effect on fetal growth requires further evaluation in a larger random controlled study.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 90%

Intra-uterine growth retardation and maternal labetatol treatment in a random allocation controlled study

Cruickshank¹,

Campbell²,

Robertson³

et al. 1992

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…Several studies have reported reductions in preterm delivery, neonatal respiratory distress syndrome, and intensive care unit treatment but no significant effects on intrauterine fetal growth in women with mild to moderate PIH who received antihypertensive medication [12,14,[35][36][37]. In a meta-analysis of antihypertensive trials for PIH, treatment of mild to moderate PIH with BP lowering drugs was associated with slight, but statistically non-significant, reduction in the rates of perinatal death (relative risk 0.71, 95% confidence interval 0.46-1.09) or preterm birth (relative risk 0.98, 95% confidence interval 0.85-1.13) [28].…”

Section: Effects Of Antihypertensive Medication On Fetal Parameters Amentioning

confidence: 99%

Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa

Molvi

Mir

Rana

et al. 2012

Arch Gynecol Obstet

View full text Add to dashboard Cite

As compared to the control group, the treatment group had lower rates of severe PIH (28% vs. 10%, P = 0.005), proteinuria (28% vs. 12%, P = 0.016), hospitalization before term (28% vs. 14%, P = 0.041), and delivery by cesarean section (38% vs. 22%, P = 0.042). In a multivariable logistic regression model that adjusted for maternal age, weight, parity, previous PIH, and baseline hemoglobin, resting heart rate, and BP levels, antihypertensive therapy was associated with a lower incidence of adverse maternal events (P = 0.011). Compared to the control group, the treatment group had lower incidence of SGA babies (40% vs. 23%, P = 0.033), preterm birth (36% vs. 14%, P = 0.002), and admission to neonatal unit (30% vs. 15%, P = 0.036). After adjustment for maternal age, weight, baseline hemoglobin, resting heart rate, BP level, parity and previous history of PIH, fetal death, preterm delivery or SGA baby, antihypertensive therapy was associated with a lower incidence of adverse perinatal events (P = 0.016). Maternal and perinatal mortality rates were not significantly different between treatment and control groups. In conclusion, pharmacological treatment of mild to moderate PIH is associated with lower rate of some maternal and fetal-neonatal non-fatal adverse events compared to no routine use of antihypertensive therapy.

show abstract

“…In our study, 3/8 children in the Iabetalol group and 8/11 in the hydralazine group were diagnosed as small for gestational age (SGA) (-2 SD). PICKLES et al [20] did observe a reduction in preterm delivery and neonatal respiratory distress syndrome and jaundice in the Iabetalol treated group compared with the placebo group. In this multicenter, double-blind, prospective study they treated mild to moderate non-proteinuric pregnancy-induced hypertension.…”

Section: Discussionmentioning

confidence: 91%

“…There is an indication in the study by PICKLES et al [20] that early iabetalol treatment could result in a higher frequency of IUGR. However, in their study 5 of the 6 IUGR children were already suspected of growth retardation before inclusion.…”

Section: Discussionmentioning

confidence: 99%

Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatment

Hjertberg¹,

Faxelius²,

Lagercrantz³

1993

Jpme

View full text Add to dashboard Cite

Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment. Arterial blood gas analysis was performed at delivery from the clamped cord. Neonatal blood pressure, heart rate and axillary temperature were registered 0.5, 2, 6, 12, 24, 36, 48 hours and 3, 4 and 7 days after birth. Respiratory rate was registered at the same intervals until 36 hours after birth. Blood glucose levels were measured 2, 6, 12 and 24 hours after birth. Peripheral blood flow in the calf was measured at 24 hours of age. Gestational age did not differ between the two groups; 36 (27-40) in the labetalol, and 35 (29-37) weeks in the hydralazine group (median and range). Median cord pH was lower, and the number of infants with a cord pH < 7.20 was higher in the hydralazine group. Blood glucose levels were lower in the labetalol group at 6 hours of age (p < 0.05). No other differences were found between the two groups. The conclusion is that no clinical signs of adrenergic blockade have been found at 24 hours of age, and no negative effect of labetalol on the neonatal adaptation compared to hydralazine antihypertensive treatment was found.

show abstract

The Fetal Outcome in a Randomized Double-Blind Controlled Trial of Labetalol versus Placebo in Pregnancy-Induced Hypertension

Cited by 12 publications

References 0 publications

Intra-uterine growth retardation and maternal labetatol treatment in a random allocation controlled study

Intra-uterine growth retardation and maternal labetatol treatment in a random allocation controlled study

Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa

Neonatal adaptation in hypertensive pregnancy — A study of labetalol vs hydralazine treatment

Contact Info

Product

Resources

About